HANGZHOU TIGERMED CONSULTING CO LTDHANGZHOU TIGERMED CONSULTING CO LTDHANGZHOU TIGERMED CONSULTING CO LTD

HANGZHOU TIGERMED CONSULTING CO LTD

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪44.10 B‬HKD
1.20HKD
‪2.24 B‬HKD
‪8.16 B‬HKD
‪123.13 M‬
Beta (1Y)
2.13
Employees (FY)
‪9.7 K‬
Change (1Y)
+468 +5.07%
Revenue / Employee (1Y)
‪841.08 K‬HKD
Net income / Employee (1Y)
‪230.83 K‬HKD

About HANGZHOU TIGERMED


CEO
Xiao Chun Cao
Headquarters
Hangzhou
Founded
2004
ISIN
CNE1000040M1
FIGI
BBG00W6R5W34
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 3347 is 31.45 HKD — it has decreased by −3.99% in the past 24 hours. Watch HANGZHOU TIGERMED CONSULTING CO LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange HANGZHOU TIGERMED CONSULTING CO LTD stocks are traded under the ticker 3347.
3347 stock has fallen by −2.95% compared to the previous week, the month change is a −4.43% fall, over the last year HANGZHOU TIGERMED CONSULTING CO LTD has showed a −5.56% decrease.
We've gathered analysts' opinions on HANGZHOU TIGERMED CONSULTING CO LTD future price: according to them, 3347 price has a max estimate of 92.22 HKD and a min estimate of 34.96 HKD. Watch 3347 chart and read a more detailed HANGZHOU TIGERMED CONSULTING CO LTD stock forecast: see what analysts think of HANGZHOU TIGERMED CONSULTING CO LTD and suggest that you do with its stocks.
3347 reached its all-time high on Jan 6, 2021 with the price of 199.90 HKD, and its all-time low was 22.10 HKD and was reached on Feb 14, 2024. View more price dynamics on 3347 chart.
See other stocks reaching their highest and lowest prices.
3347 stock is 5.17% volatile and has beta coefficient of 2.13. Track HANGZHOU TIGERMED CONSULTING CO LTD stock price on the chart and check out the list of the most volatile stocks — is HANGZHOU TIGERMED CONSULTING CO LTD there?
Today HANGZHOU TIGERMED CONSULTING CO LTD has the market capitalization of ‪28.04 B‬, it has decreased by −6.64% over the last week.
Yes, you can track HANGZHOU TIGERMED CONSULTING CO LTD financials in yearly and quarterly reports right on TradingView.
HANGZHOU TIGERMED CONSULTING CO LTD is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
3347 earnings for the last quarter are 0.40 HKD per share, whereas the estimation was 0.59 HKD resulting in a −31.55% surprise. The estimated earnings for the next quarter are 0.61 HKD per share. See more details about HANGZHOU TIGERMED CONSULTING CO LTD earnings.
HANGZHOU TIGERMED CONSULTING CO LTD revenue for the last quarter amounts to ‪1.87 B‬ HKD, despite the estimated figure of ‪2.22 B‬ HKD. In the next quarter, revenue is expected to reach ‪2.17 B‬ HKD.
3347 net income for the last quarter is ‪348.84 M‬ HKD, while the quarter before that showed ‪278.26 M‬ HKD of net income which accounts for 25.36% change. Track more HANGZHOU TIGERMED CONSULTING CO LTD financial stats to get the full picture.
Yes, 3347 dividends are paid annually. The last dividend per share was 0.62 HKD. As of today, Dividend Yield (TTM)% is 1.92%. Tracking HANGZHOU TIGERMED CONSULTING CO LTD dividends might help you take more informed decisions.
HANGZHOU TIGERMED CONSULTING CO LTD dividend yield was 1.76% in 2023, and payout ratio reached 24.09%. The year before the numbers were 0.68% and 22.70% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 27, 2024, the company has ‪9.70 K‬ employees. See our rating of the largest employees — is HANGZHOU TIGERMED CONSULTING CO LTD on this list?
Like other stocks, 3347 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANGZHOU TIGERMED CONSULTING CO LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANGZHOU TIGERMED CONSULTING CO LTD technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANGZHOU TIGERMED CONSULTING CO LTD stock shows the sell signal. See more of HANGZHOU TIGERMED CONSULTING CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.